+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 38 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the pharmacokinetics, safety, and immune response of two drugs, RPH-030 and Vectibix4, in patients with metastatic colorectal cancer mCRC who have wild-type RAS genes. The study aims to show that these treatments are equivalent in how the body processes them and to compare their safety and immune effects. Additionally, the study will explore how effective these drugs are when used as first-line therapy combined with FOLFIRI chemotherapy. Participants will receive either RPH-030 or Vectibix4 intravenously at 6 mgkg every two weeks along with FOLFIRI chemotherapy, which includes irinotecan, calcium folinate, and fluorouracil. Treatment starts with FOLFIRI for 8 cycles, then continues with a modified de Gramont regimen. The study includes several periods a screening phase, a main period lasting up to 6 months, a continued therapy period up to 1 year where all patients receive RPH-030, and a treatment extension period lasting up to 2 years for patients with stable disease or response. Follow-up visits occur after treatment ends to monitor survival and disease status. Participants will undergo regular tumor assessments approximately every 6 to 8 weeks, hospitalizations for drug administration at specific visits, and blood sampling for pharmacokinetic and safety evaluations. Researchers will monitor drug levels over time, adverse events, immune reactions, and tumor responses. Follow-up includes imaging or phone calls to track overall survival and disease progression. The total study participation can last up to about 2 years with additional follow-up to ensure thorough monitoring of outcomes and safety.

Age: 18Years +All GendersPhase 1
26 locations
P

Actively Recruiting

This research aims to evaluate the safety and early effects of vitamin K2 menaquinone-7, MK-7 supplementation in adults aged 40 to 75 years with low bone mineral density, including osteopenia or osteoporosis. The study focuses on individuals carrying a specific unfavorable variant in the vitamin D receptor VDR gene, comparing them to those without this gene variant. The goal is to see if MK-7 supplementation improves bone health and related markers more in the variant group, who may have a reduced response to vitamin D. Participants will receive vitamin K2 menaquinone-7 at doses of 100 to 200 micrograms per day along with vitamin D3 at 800 to 1000 IU per day for a period of 6 to 9 months. The study has two groups one with homozygous carriers of the VDR variant and one control group without the variant. Both groups will follow the same supplementation regimen to compare outcomes related to bone health. During the study, participants will be monitored for changes in bone mineral density over 9 months, along with serum osteocalcin levels, bone turnover markers, vitamin D levels, and quality of life measures. Safety and tolerability will be assessed by recording any treatment-related adverse events. Participants will maintain stable diets and exercise routines, and genotyping will confirm their group assignment. Total participation will last up to 9 months with regular assessments.

Age: 40Years - 75YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.

Age: 18Years +All GendersPhase 3
28 locations
L

Actively Recruiting

This research aims to provide continued access to study treatments for participants with pulmonary hypertension who have completed previous clinical studies but have no other treatment alternatives. The study evaluates the long-term safety of these treatments, including macitentan, selexipag, and a fixed dose combination of macitentan and tadalafil. It is a phase 3, open-label study sponsored by Actelion. Participants who have completed parent studies and still benefit from their assigned treatment will continue receiving their study drug orally during this follow-up study. Adults typically take macitentan once daily, selexipag twice daily at their maintenance dose, or the macitentantadalafil combination once daily. Children aged 2 years and older receive doses adjusted by body weight. Study visits occur every 6 months for adults and every 3 months for pediatric participants, continuing until treatment becomes commercially available, an equivalent therapy is accessible, the participant withdraws, or the study ends early. During the study, participants undergo regular assessments to monitor safety and treatment effects, including collection of adverse event data, treatment discontinuations, serious adverse events, and deaths over up to 84 months. Visits include on-site evaluations of efficacy and safety. This long-term monitoring helps researchers understand the safety profile of these treatments when used beyond the initial clinical trials.

Age: 2Years +All GendersPhase 3
45 locations
C

Actively Recruiting

Researchers are evaluating the investigational drug GNR-139 compared to the reference drug Eylea in patients with neovascular age-related macular degeneration nAMD who have not received prior treatment. This multicenter, randomized, double-blind study aims to assess whether GNR-139 has similar effectiveness and safety as Eylea by measuring changes in visual acuity. Participants will be randomly assigned in a 21 ratio to receive either GNR-139 or Eylea, both administered as an 8 mg intravitreal injection. The study includes two groups 120 patients receiving GNR-139 and 60 patients receiving Eylea. Treatments are given by injection into the eye, and neither participants nor doctors know which drug is given. Throughout the study, participants will have their visual acuity measured using the ETDRS chart at multiple time points up to Week 56. Optical coherence tomography OCT and fluorescein angiography FFA will assess retinal changes and lesion areas. Researchers will monitor safety, immunogenicity, and treatment effects over one year, including tracking the number of injections and any adjustments needed in treatment intervals.

Age: 50Years +All GendersPhase 3
14 locations
O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
S

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and pharmacodynamics of a single dose of ANB-002, a gene therapy, in adult men with hemophilia B who have low factor IX FIX activity and no FIX inhibitor. The study aims to show that ANB-002 is not less effective than standard preventive treatment using FIX concentrates. This is an open-label, phase 3 trial sponsored by Biocad. Participants first undergo a non-interventional lead-in period lasting at least six months during which they receive standard FIX preventive treatment. After this, they enter the main interventional period where they receive a single infusion of ANB-002. This main period lasts 18 months, followed by a follow-up period of up to five years after the ANB-002 infusion. During the study, researchers will monitor participants bleeding rates before and after treatment, FIX activity levels, and FIX concentrate use. They will also assess the proportion of subjects not needing FIX prevention, and track various bleeding events including spontaneous bleedings and hemarthrosis. Safety and treatment effects will be evaluated over the long-term follow-up, with study participation lasting up to five years after treatment.

Age: 18Years +MALEPhase 3
14 locations
O

Actively Recruiting

Researchers are investigating the link between persistent Helicobacter pylori infection and the severity of insulin resistance in 100 patients diagnosed with metabolic syndrome. This retrospective cohort study aims to clarify how chronic H. pylori-related inflammation may worsen metabolic factors related to insulin resistance, a key component of metabolic syndrome that contributes to type 2 diabetes, liver disease, and cardiovascular problems. Participants are divided into two groups those with metabolic syndrome who have persistent H. pylori infection and those without the infection. The study evaluates metabolic markers, including insulin resistance measured by the HOMA-IR index, along with inflammatory markers like C-reactive protein CRP and various metabolic parameters such as body mass index, waist circumference, fasting glucose, and cholesterol levels. Measurements are taken within two days of study inclusion. During participation, patients undergo fasting blood tests, breath tests, stool antigen tests, and possibly endoscopy with biopsy to confirm infection status and metabolic parameters. Researchers will compare insulin resistance levels and correlations with inflammation and metabolic markers between infected and non-infected groups. The study is observational and does not include treatment interventions, with participation lasting through the data collection period shortly after inclusion.

Age: 18Years - 65YearsAll Genders
1 location
S

Actively Recruiting

Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.

Age: 18Years - 74YearsFEMALEPhase 2
47 locations
R

Actively Recruiting

Researchers are studying patients with atherosclerotic carotid stenosis, including both symptomatic patients with stenosis over 50% and asymptomatic patients with stenosis 80% or greater. This trial compares early neurological outcomes using two different embolic protection devices combined with the CGuard microNet covered stent. The purpose is to evaluate whether distal or proximal embolic protection device placement offers better results, expanding on previous findings that showed CGuard stent implantation had advantages over classical stents using distal protection. Participants will undergo carotid artery stenting with one of two devices the Emboshield NAV6 distal embolic protection system plus the CGuard stent, or the Mo.Ma proximal cerebral protection device plus the CGuard stent. The study groups are randomized and unblinded, and both devices aim to reduce embolic events during the stenting procedure. The trial began in November 2021 and will continue until January 2027. During the study, participants will receive neurological assessments and brain imaging to detect ischemic lesions within 24 to 48 hours after the procedure. The primary outcome is the determination of these ischemic lesions, while secondary outcomes include monitoring major adverse cardiac and cerebrovascular events during and shortly after the procedure. Participants must consent to follow-up visits and procedures as part of the trial involvement.

Age: 45Years - 80YearsAll GendersPhase Not Applicable
1 location

1-10 of 38

1